Blüher Matthias
Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
J Obes Metab Syndr. 2024 Dec 30;33(4):275-288. doi: 10.7570/jomes24013.
Diseases affecting adipose tissue (AT) function include obesity, lipodystrophy, and lipedema, among others. Both a lack of and excess AT are associated with increased risk for developing diseases including type 2 diabetes mellitus, hypertension, obstructive sleep apnea, and some types of cancer. However, individual risk of developing cardiometabolic and other 'obesity-related' diseases is not entirely determined by fat mass. Rather than excess fat accumulation, AT dysfunction may represent the mechanistic link between obesity and comorbid diseases. There are people who remain metabolically healthy despite obesity, whereas people with normal weight or very low subcutaneous AT mass may develop typically obesity-related diseases. AT dysfunction is characterized by adipocyte hypertrophy, impaired subcutaneous AT expandability (ectopic fat deposition), hypoxia, a variety of stress, inflammatory processes, and the release of proinflammatory, diabetogenic, and atherogenic signals. Genetic and environmental factors might contribute to AT heterogeneity either alone or via interaction with intrinsic biological factors. However, many questions remain regarding the mechanisms of AT dysfunction initiation and whether and how it could be reversed. Do AT signatures define clinically relevant subtypes of obesity? Is the cellular composition of AT associated with variation in obesity phenotypes? What roles do environmental compounds play in the manifestation of AT dysfunction? Answers to these and other questions may explain AT disease mechanisms and help to define strategies for improving AT health. This review focuses on recent advances in our understanding of AT biology.
影响脂肪组织(AT)功能的疾病包括肥胖症、脂肪营养不良和脂肪水肿等。AT缺乏和过多都与患2型糖尿病、高血压、阻塞性睡眠呼吸暂停和某些类型癌症等疾病的风险增加有关。然而,个体患心脏代谢疾病和其他“肥胖相关”疾病的风险并不完全由脂肪量决定。AT功能障碍而非过多的脂肪堆积,可能代表了肥胖与合并症之间的机制联系。有些人尽管肥胖但仍保持代谢健康,而体重正常或皮下AT量极低的人可能会患上典型的肥胖相关疾病。AT功能障碍的特征是脂肪细胞肥大、皮下AT扩张能力受损(异位脂肪沉积)、缺氧、各种应激、炎症过程以及促炎、致糖尿病和致动脉粥样硬化信号的释放。遗传和环境因素可能单独或通过与内在生物因素的相互作用导致AT异质性。然而,关于AT功能障碍起始机制以及它是否可以逆转以及如何逆转,仍有许多问题。AT特征是否定义了临床上相关的肥胖亚型?AT的细胞组成是否与肥胖表型的变化有关?环境化合物在AT功能障碍的表现中起什么作用?对这些及其他问题的回答可能解释AT疾病机制,并有助于确定改善AT健康的策略。本综述重点关注我们对AT生物学理解的最新进展。